Skip to main content
Erschienen in:

07.12.2018 | Review

Systematic Review: Efficacy and Safety of Accelerated Induction Regimes in Infliximab Rescue Therapy for Hospitalized Patients with Acute Severe Colitis

verfasst von: S. Sebastian, S. Myers, S. Nadir, S. Subramanian

Erschienen in: Digestive Diseases and Sciences | Ausgabe 5/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

Pharmacokinetic data suggest that standard induction dosing schedules may not be sufficient in patients with acute severe colitis (ASUC). Hence, intensified induction regimes are increasingly used in the rescue treatment of hospitalized patients with ASUC to avoid the need for colectomy although the evidence for this is uncertain.

Aim

To conduct a systematic review of short- and long-term efficacy outcomes from accelerated infliximab induction studies.

Methods

Systematic search of relevant databases (MEDLINE, EMBASE, Cochrane Database of Systematic Reviews) and relevant conference proceedings (Digestive Diseases Week, European Colitis and Crohn’s Organisation Congress, United European Gastroenterology Week) was done.

Results

We identified ten relevant studies with a total of 705 patients, of whom 308 received an intensified infliximab regime. Pooled analysis showed no difference in short-term or long-term colectomy rates in those receiving accelerated induction regimes when compared to standard induction. No significant differences in complication rates were identified.

Conclusions

The available uncontrolled studies so far do not suggest short-term or long-term benefit in using accelerated induction in hospitalized ASUC. The overall poor quality of available studies with confounding variables indicates the need for a randomized controlled trial with personalized risk stratification.
Literatur
1.
Zurück zum Zitat Domenech E, Manosa M, Cabre E. An overview of the natural history of inflammatory bowel diseases. Dig Dis. 2014;32:320–327.CrossRefPubMed Domenech E, Manosa M, Cabre E. An overview of the natural history of inflammatory bowel diseases. Dig Dis. 2014;32:320–327.CrossRefPubMed
2.
Zurück zum Zitat Ananthakrishnan AN, McGinley EL, Binion DG, et al. A nationwide analysis of changes in severity and outcomes of inflammatory bowel disease hospitalizations. J Gastrointest Surg. 2011;15:267–276.CrossRefPubMed Ananthakrishnan AN, McGinley EL, Binion DG, et al. A nationwide analysis of changes in severity and outcomes of inflammatory bowel disease hospitalizations. J Gastrointest Surg. 2011;15:267–276.CrossRefPubMed
3.
Zurück zum Zitat Hardy TL, Bulmer E. Ulcerative colitis: a survey of ninety-five cases. Br Med Journal. 1933;2:812–815.CrossRef Hardy TL, Bulmer E. Ulcerative colitis: a survey of ninety-five cases. Br Med Journal. 1933;2:812–815.CrossRef
4.
Zurück zum Zitat Brown SR, Haboubi N, Hampton J, George B, Travis SP. The management of acute severe colitis: ACPGBI position statement. Colorectal Dis. 2008;10:8–29.CrossRefPubMed Brown SR, Haboubi N, Hampton J, George B, Travis SP. The management of acute severe colitis: ACPGBI position statement. Colorectal Dis. 2008;10:8–29.CrossRefPubMed
5.
Zurück zum Zitat Turner D, Walsh CM, Steinhart AH, Griffiths AM. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol. 2007;5:103–110.CrossRefPubMed Turner D, Walsh CM, Steinhart AH, Griffiths AM. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol. 2007;5:103–110.CrossRefPubMed
6.
Zurück zum Zitat Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994;330:1841–1845.CrossRefPubMed Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994;330:1841–1845.CrossRefPubMed
7.
Zurück zum Zitat Van Assche G, D’Haens G, Normal M, et al. Randomised, double blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology. 2003;125:1025–1031.CrossRefPubMed Van Assche G, D’Haens G, Normal M, et al. Randomised, double blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology. 2003;125:1025–1031.CrossRefPubMed
8.
Zurück zum Zitat Sands BE, Tremaine WJ, Sandborn WJ, et al. Infliximab in the treatment of severe, steroid -refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis. 2001;7:83–88.CrossRefPubMed Sands BE, Tremaine WJ, Sandborn WJ, et al. Infliximab in the treatment of severe, steroid -refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis. 2001;7:83–88.CrossRefPubMed
9.
Zurück zum Zitat Probert CS, Hearing SD, Schreiber S, et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut. 2003;52:998–1002.CrossRefPubMedPubMedCentral Probert CS, Hearing SD, Schreiber S, et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut. 2003;52:998–1002.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Jarnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomised, placebo-controlled study. Gastroenterology. 2005;128:1805–1811.CrossRefPubMed Jarnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomised, placebo-controlled study. Gastroenterology. 2005;128:1805–1811.CrossRefPubMed
11.
Zurück zum Zitat Chaparro M, Burgueno P, Iglesias E, et al. Infliximab salvage therapy after failure of ciclosporin in corticosteroid ulcerative colitis: a multicentric study. Aliment Pharmacol Ther. 2012;35:275–283.CrossRefPubMed Chaparro M, Burgueno P, Iglesias E, et al. Infliximab salvage therapy after failure of ciclosporin in corticosteroid ulcerative colitis: a multicentric study. Aliment Pharmacol Ther. 2012;35:275–283.CrossRefPubMed
12.
Zurück zum Zitat Lees CW, Heys D, Ho GT, et al. A retrospective analysis of the efficacy and safety of infliximab as a rescue therapy in acute severe ulcerative colitis. Aliment Pharmacol Ther. 2007;26:411–419.CrossRefPubMed Lees CW, Heys D, Ho GT, et al. A retrospective analysis of the efficacy and safety of infliximab as a rescue therapy in acute severe ulcerative colitis. Aliment Pharmacol Ther. 2007;26:411–419.CrossRefPubMed
13.
Zurück zum Zitat Sjoberg M, Magnuson A, Bjork J, et al. Infliximab as rescue therapy in hospitalised patients with steroid-refractory acute ulcerative colitis: a long term follow up of 211 Swedish patients. Aliment Pharmacol Ther. 2013;38:377–387.CrossRefPubMed Sjoberg M, Magnuson A, Bjork J, et al. Infliximab as rescue therapy in hospitalised patients with steroid-refractory acute ulcerative colitis: a long term follow up of 211 Swedish patients. Aliment Pharmacol Ther. 2013;38:377–387.CrossRefPubMed
14.
Zurück zum Zitat Laharie D, Bourreille A, Branche J, et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet.. 2012;380:1909–1915.CrossRefPubMed Laharie D, Bourreille A, Branche J, et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet.. 2012;380:1909–1915.CrossRefPubMed
15.
Zurück zum Zitat Laharie D, Bourreille A, Branche J, et al. Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporine or infliximab. Gut. 2018;67:237–243.CrossRefPubMed Laharie D, Bourreille A, Branche J, et al. Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporine or infliximab. Gut. 2018;67:237–243.CrossRefPubMed
16.
Zurück zum Zitat Williams JG, Alam MF, Alrubaiy L, et al. Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed method, open-label, pragmatic randomised trial. Lancet Gastroenterol Hepatol. 2016;1:15–24.CrossRefPubMedPubMedCentral Williams JG, Alam MF, Alrubaiy L, et al. Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed method, open-label, pragmatic randomised trial. Lancet Gastroenterol Hepatol. 2016;1:15–24.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Tottrup A, Erichsen R, Svaerke C, et al. Thirty-day mortality after elective and emergency total colectomy in Danish patients with inflammatory bowel disease: a population-based nationwide cohort study. BMJ Open. 2012;2:e000823.CrossRefPubMedPubMedCentral Tottrup A, Erichsen R, Svaerke C, et al. Thirty-day mortality after elective and emergency total colectomy in Danish patients with inflammatory bowel disease: a population-based nationwide cohort study. BMJ Open. 2012;2:e000823.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Ungar B, Mazoor R, Weisshof R, et al. Induction infliximab levels among patients with acute severe ulcerative colitis compared with patients with moderately severe ulcerative colitis. Aliment Pharmacol Ther. 2016;43:1293–1299.CrossRefPubMed Ungar B, Mazoor R, Weisshof R, et al. Induction infliximab levels among patients with acute severe ulcerative colitis compared with patients with moderately severe ulcerative colitis. Aliment Pharmacol Ther. 2016;43:1293–1299.CrossRefPubMed
19.
Zurück zum Zitat Yarur AJ, Jain A, Sussman DA, et al. The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study. Gut. 2016;65:249–255.CrossRefPubMed Yarur AJ, Jain A, Sussman DA, et al. The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study. Gut. 2016;65:249–255.CrossRefPubMed
20.
Zurück zum Zitat Brandse JF, van den Brink GR, Wildenberg ME, et al. Loss of infliximab into faeces is associated with lack of response to therapy in patients with severe ulcerative colitis. Gastroenterology. 2015;149:350–355 e2.CrossRefPubMed Brandse JF, van den Brink GR, Wildenberg ME, et al. Loss of infliximab into faeces is associated with lack of response to therapy in patients with severe ulcerative colitis. Gastroenterology. 2015;149:350–355 e2.CrossRefPubMed
21.
Zurück zum Zitat Fasanmade AA, Adedokun OJ, Ford J, et al. Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis. Eur J Clin Pharmacol. 2009;65:1211–1228.CrossRefPubMedPubMedCentral Fasanmade AA, Adedokun OJ, Ford J, et al. Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis. Eur J Clin Pharmacol. 2009;65:1211–1228.CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Rosen MJ, Minar P, Vinks AA. Review article: applying pharmacokinetics to optimise dosing of anti-TNF biologics in acute severe colitis. Aliment Pharmacol Ther. 2015;41:1094–1103.CrossRefPubMedPubMedCentral Rosen MJ, Minar P, Vinks AA. Review article: applying pharmacokinetics to optimise dosing of anti-TNF biologics in acute severe colitis. Aliment Pharmacol Ther. 2015;41:1094–1103.CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Herfarth HH, Rogler G, Higgins PDR. Pushing the pedal to the metal: should we accelerate infliximab therapy for patients with severe ulcerative colitis. Clin Gastroenterol Hepatol. 2015;13:336–338.CrossRefPubMed Herfarth HH, Rogler G, Higgins PDR. Pushing the pedal to the metal: should we accelerate infliximab therapy for patients with severe ulcerative colitis. Clin Gastroenterol Hepatol. 2015;13:336–338.CrossRefPubMed
26.
Zurück zum Zitat Gibson DJ, Heetun ZS, Redmond CE, Nanda KS, Keegan D, Byrne K, et al. An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis. Clin Gastroenterol Hepatol. 2015;13:330–335e1. Gibson DJ, Heetun ZS, Redmond CE, Nanda KS, Keegan D, Byrne K, et al. An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis. Clin Gastroenterol Hepatol. 2015;13:330–335e1.
27.
Zurück zum Zitat Sly N, Werner S, Pitt R, et al. Accelerated dosing of infliximab is not associated with improved colectomy rates in hospitalized severe ulcerative colitis patients. Am J Gastroenterol. 2017;8:S189. Sly N, Werner S, Pitt R, et al. Accelerated dosing of infliximab is not associated with improved colectomy rates in hospitalized severe ulcerative colitis patients. Am J Gastroenterol. 2017;8:S189.
28.
Zurück zum Zitat Shah SC, Naymagon S, Panchal HJ, et al. Accelerated infliximab dosing increases 30-day colectomy in hospitalized ulcerative colitis patients: a propensity score analysis. Inflamm Bowel Dis. 2018;24:651–659.CrossRefPubMed Shah SC, Naymagon S, Panchal HJ, et al. Accelerated infliximab dosing increases 30-day colectomy in hospitalized ulcerative colitis patients: a propensity score analysis. Inflamm Bowel Dis. 2018;24:651–659.CrossRefPubMed
29.
Zurück zum Zitat Choy MC, Seah D, Gorelik A, et al. Predicting response after infliximab salvage in acute severe ulcerative colitis. J Gastroenterol Hepatol. 2018;33:1347–1352.CrossRefPubMed Choy MC, Seah D, Gorelik A, et al. Predicting response after infliximab salvage in acute severe ulcerative colitis. J Gastroenterol Hepatol. 2018;33:1347–1352.CrossRefPubMed
30.
Zurück zum Zitat Govani SM, Waljee AK, Stidham RW, et al. Accelerated dosing of infliximab prevents colectomy within 90 days in only half of patients with severe ulcerative colitis. Gastroenterology. 2016;150:S106.CrossRef Govani SM, Waljee AK, Stidham RW, et al. Accelerated dosing of infliximab prevents colectomy within 90 days in only half of patients with severe ulcerative colitis. Gastroenterology. 2016;150:S106.CrossRef
31.
Zurück zum Zitat Singh KS, Hart L, Al Khoury A, et al. Standard versus intensified infliximab rescue therapy for hospitalised paediatric patients with acute severe exacerbations of colitis-predominant inflammatory bowel disease. J Crohn`s Colitis. 2018; P667. Singh KS, Hart L, Al Khoury A, et al. Standard versus intensified infliximab rescue therapy for hospitalised paediatric patients with acute severe exacerbations of colitis-predominant inflammatory bowel disease. J Crohn`s Colitis. 2018; P667.
32.
Zurück zum Zitat Al Khoury A, Chao C, Aruljothy A, et al. Intensified infliximab rescue therapy for acute severe ulcerative colitis does not improve long term colectomy-free survival. J Crohn`s Colitis. 2017;P495. Al Khoury A, Chao C, Aruljothy A, et al. Intensified infliximab rescue therapy for acute severe ulcerative colitis does not improve long term colectomy-free survival. J Crohn`s Colitis. 2017;P495.
33.
Zurück zum Zitat Gibson DJ, Doherty J, McNally M, et al. Medium to long-term outcomes in patients receiving accelerated dose infliximab induction for acute severe ulcerative colitis (ASUC) in a multicentre cohort. Gastroenterology. 2018;S 318. Gibson DJ, Doherty J, McNally M, et al. Medium to long-term outcomes in patients receiving accelerated dose infliximab induction for acute severe ulcerative colitis (ASUC) in a multicentre cohort. Gastroenterology. 2018;S 318.
35.
Zurück zum Zitat Nalagatla N, Falloon K, Gloria T, et al. Effect of accelerated infliximab induction on short and long-term outcomes of acute severe ulcerative colitis: a retrospective multicentre study and metaanalysis. Clinical Gastroenterol Hepatol. 2018 (in press). Nalagatla N, Falloon K, Gloria T, et al. Effect of accelerated infliximab induction on short and long-term outcomes of acute severe ulcerative colitis: a retrospective multicentre study and metaanalysis. Clinical Gastroenterol Hepatol. 2018 (in press).
36.
Zurück zum Zitat Rofaiel R, Kohli S, Mura M, et al. A 53-year-old man with dyspnoea, respiratory failure, consistent with infliximab induced acute interstitial pneumonitis after an accelerated induction dosing schedule. BMJ Case Rep. 2017;12:2017. Rofaiel R, Kohli S, Mura M, et al. A 53-year-old man with dyspnoea, respiratory failure, consistent with infliximab induced acute interstitial pneumonitis after an accelerated induction dosing schedule. BMJ Case Rep. 2017;12:2017.
37.
Zurück zum Zitat Kevans D, Murthy SJ, Iacono A, et al. Accelerated clearance of serum infliximab during induction therapy for acute ulcerative colitis is associated with treatment failure. Gastroenterology. 2012;142:S 384. Kevans D, Murthy SJ, Iacono A, et al. Accelerated clearance of serum infliximab during induction therapy for acute ulcerative colitis is associated with treatment failure. Gastroenterology. 2012;142:S 384.
38.
Zurück zum Zitat Brandse JF, Mathot RA, van der Kleij D, et al. Pharmacokinetic features and presence of antidrug antibodies associated with response to infliximab induction therapy in patients with moderate to severe ulcerative colitis. Clin Gastroenterol Hepatol. 2016;14:251–258.CrossRefPubMed Brandse JF, Mathot RA, van der Kleij D, et al. Pharmacokinetic features and presence of antidrug antibodies associated with response to infliximab induction therapy in patients with moderate to severe ulcerative colitis. Clin Gastroenterol Hepatol. 2016;14:251–258.CrossRefPubMed
39.
Zurück zum Zitat Shah SC, Naymagon S, Cohen BL, et al. There is significant practice pattern variability in the management of the hospitalized ulcerative colitis patient at a tertiary care and IBD referral centre. J Clin Gastroenterol. 2018;52:333–338. Shah SC, Naymagon S, Cohen BL, et al. There is significant practice pattern variability in the management of the hospitalized ulcerative colitis patient at a tertiary care and IBD referral centre. J Clin Gastroenterol. 2018;52:333–338.
40.
Zurück zum Zitat Ho GT, Mowat C, Goddard CJ, et al. Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second line medical therapy or surgery. Aliment Pharmacol Ther. 2004;19:1079–1087.CrossRefPubMed Ho GT, Mowat C, Goddard CJ, et al. Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second line medical therapy or surgery. Aliment Pharmacol Ther. 2004;19:1079–1087.CrossRefPubMed
42.
Zurück zum Zitat Papa Michael K, Rivas-Lerebours O, Billiet T, et al. Long-term outcome of patients with ulcerative colitis and primary non-response to infliximab. J Crohn`s Colitis. 2016;10:1015–1023. Papa Michael K, Rivas-Lerebours O, Billiet T, et al. Long-term outcome of patients with ulcerative colitis and primary non-response to infliximab. J Crohn`s Colitis. 2016;10:1015–1023.
43.
Zurück zum Zitat Beswick L, Rosella O, Rosella G et al. Exploration of predictive biomarkers of early infliximab response in acute severe colitis: a prospective pilot study. J Crohn`s Colitis. 2018;12:289–297. Beswick L, Rosella O, Rosella G et al. Exploration of predictive biomarkers of early infliximab response in acute severe colitis: a prospective pilot study. J Crohn`s Colitis. 2018;12:289–297.
Metadaten
Titel
Systematic Review: Efficacy and Safety of Accelerated Induction Regimes in Infliximab Rescue Therapy for Hospitalized Patients with Acute Severe Colitis
verfasst von
S. Sebastian
S. Myers
S. Nadir
S. Subramanian
Publikationsdatum
07.12.2018
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 5/2019
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-018-5407-7

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Neu im Fachgebiet Innere Medizin

Chemoembolisation bei HCC frühzeitig mit Checkpoint-Inhibitor kombinieren?

Beim hepatozellulären Karzinom scheint sich eine neue Therapieoption abzuzeichnen: In zwei randomisierten Studien ließ sich das progressionsfreie Überleben mit der Kombination aus Chemoembolisation, Checkpoint-Inhibitor und antiangiogener Therapie signifikant verbessern. 

Antikörper-Wirkstoff-Konjugat hält Brusttumoren langfristig in Schach

Erreichen Frauen mit HER2-positivem Mammakarzinom nach einer neoadjuvanten Therapie keine Komplettremission, bietet eine Therapie mit Trastuzumab Emtansin langfristig Vorteile: Die Sterberate ist im Vergleich zu einer Trastuzumab-Therapie um ein Drittel reduziert.

Studie zur HIFU bei Prostatakrebs lässt viele Fragen offen

Führt eine HIFU-Ablation beim Prostatakarzinom im Vergleich mit einer radikalen Prostatektomie zu ähnlichen onkologischen, aber besseren funktionalen Ergebnissen? Interimsdaten der französischen HIFI-Studie sind uneindeutig. In einem Kommentar zur Studie werden zumindest drei allgemeine Erkenntnisse herausgearbeitet.

Leitlinienkonformes Management thermischer Verletzungen

Thermische Verletzungen gehören zu den schwerwiegendsten Traumen und hinterlassen oft langfristige körperliche und psychische Spuren. Die aktuelle S2k-Leitlinie „Behandlung thermischer Verletzungen im Kindesalter (Verbrennung, Verbrühung)“ bietet eine strukturierte Übersicht über das empfohlene Vorgehen.

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.